Budapest, Hungary

Janos Pinter


Average Co-Inventor Count = 7.3

ph-index = 3

Forward Citations = 190(Granted Patents)


Company Filing History:


Years Active: 1991-1995

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Janos Pinter: Innovator in Transdermal Compositions

Introduction

Janos Pinter is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of transdermal compositions. With a total of 3 patents to his name, Pinter continues to push the boundaries of innovation in his area of expertise.

Latest Patents

Pinter's latest patents include groundbreaking work on transdermal compositions. One of his notable inventions is an anhydrous transdermal composition that comprises a 20 to 100% lyotropic liquid crystalline arrangement. Additionally, he has developed a graft lyotropic liquid crystalline composition characterized by a viscosity of less than 10 Pa.s. This composition includes a low amount of surfactants, optional co-surfactants, and/or solvents, and may also contain a polymer in a relative stretched state, which is partly or totally penetrable by the medium, along with a solid material having a surface free energy of 18 to 240 mN/m.

Career Highlights

Janos Pinter is associated with Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt., a company known for its contributions to the pharmaceutical industry. His work at this organization has allowed him to focus on innovative solutions that enhance drug delivery systems.

Collaborations

Throughout his career, Pinter has collaborated with esteemed colleagues such as Andras Szego and Katalin Marmarosi Nee Kellner. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in their respective fields.

Conclusion

Janos Pinter is a distinguished inventor whose work in transdermal compositions has made a significant impact in the pharmaceutical industry. His innovative patents and collaborations highlight his commitment to advancing drug delivery technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…